Overview

Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML

Status:
Completed
Trial end date:
2006-06-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out the effectiveness and side effects of arsenic trioxide in combination with low-dose ara-C.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Weill Medical College of Cornell University
Treatments:
Arsenic Trioxide
Cytarabine